ARTICLE | Clinical News
Centocor regulatory update
November 21, 1994 8:00 AM UTC
Centocor Inc. (CNTO) Sweden approved the Malvern, Penn., company's ReoPro GPIIb/IIIa inhibitor to treat high-risk angioplasty, marking the product's first approval. ReoPro is a monoclonal antibody d...